How diabetes can disrupt heart repair cells before old age

Since the previous research note · Partly supported

Track continuity

Since the previous research note: How ageing immune cells may strain the diabetic heart’s fuel system

Previous expectation: Targeting harmful senescent cells might help people with type 2 diabetes retain heart-muscle function if causal links, selective targeting and patient benefit could be established.

What this study adds: The May 2022 study reports restored expansion and differentiation in cultured human cardiac stem/progenitor cells after senescent-cell clearance and improved cardiac function in diabetic mice. This supports an experimental route toward the broader expectation but does not directly test the earlier immune-cell and fuel-metabolism explanation or establish benefit in patients.

---

What changed in this study

A heart’s ability to repair itself depends partly on cells that can multiply and develop into muscle-related cells. The May 2022 study behind this article asks whether diabetes can impair that repair population before advanced age, and whether removing damaged cells can improve its performance.

The researchers examined cardiac stem and progenitor cells, often abbreviated as CSCs, from people with type 2 diabetes and from a nondiabetic comparison group. They also tested a combination of drugs that clears senescent cells in cell cultures and in young diabetic mice. The results connect diabetes with an aging-associated cell state, but the evidence comes from surgical tissue, laboratory cultures and mice rather than treated patients.

Diabetes can burden repair cells before old age

The human samples came from patients undergoing cardiac surgery for ischemic heart disease. The comparison was therefore between people with and without type 2 diabetes in a clinical setting, not between diabetes and perfect health. The patients were in a restricted age range, broadly in their 50s and early 60s, and the groups were matched for age and sex.

Within that setting, the diabetic heart samples showed more oxidative stress and a stronger senescent phenotype in cells enriched for cardiac stem and progenitor cells. Their cells also performed less well in culture. Compared with cells from the nondiabetic group, diabetic CSCs had reduced growth, weaker capacity to form cell clusters and less ability to adopt a muscle-cell program.

The age comparison matters because cellular senescence and organismal aging are related but not identical. A cell can enter senescence after stressful damage even when the person or animal is not old. The study’s central possibility is that diabetes may create some of the biological conditions associated with aging inside a repair-related cell population earlier than expected.

When a repair cell becomes senescent

Cellular senescence is a persistent change in cell state. A senescent cell generally stops progressing through the cell cycle and develops other alterations, including changes in metabolism and secretion. For a tissue that depends on a supply of responsive progenitor cells, a larger pool of cells that no longer expand or differentiate normally could reduce its ability to respond to injury.

The senescence-associated secretory phenotype, or SASP, describes the substances senescent cells release. Those secreted signals can change the environment around the cells. In this study, diabetic human CSCs showed a defined pathological SASP alongside oxidative stress and impaired growth and differentiation. The researchers therefore treated senescence and SASP as candidate mechanisms linking diabetes to weaker cardiac repair.

That interpretation remains mechanistic rather than clinical. The human tissue comparison shows that diabetes and the senescent CSC phenotype appeared together in these surgical samples. It does not by itself show that senescence was the sole cause of the cells’ reduced performance, or that the same pattern applies to every person with diabetes.

Clearing cells changed the culture

The researchers next tested dasatinib plus quercetin, a two-drug combination used in the experiments as a senolytic treatment. In cultures of human diabetic CSCs, the combination cleared senescent cells. The remaining population then regained the ability to expand and showed improved capacity for myogenic differentiation, meaning development toward a muscle-cell state.

The important result is a population-level change. The experiment did not demonstrate that each senescent cell was repaired or returned to its former state. Instead, after senescent cells were removed, cells capable of growth and differentiation became more prominent in the culture. That is a different idea from rejuvenating every damaged cell.

The culture experiment also answers a narrower question than a treatment study would. It shows that senescent-cell clearance can alter the behavior of isolated human cardiac cells under laboratory conditions. It does not show that the same combination is a safe or effective regimen for people, nor that the cultured cells would produce durable heart-function benefits in the body.

The mouse result adds organ-level evidence

The researchers then moved from cultured human cells to a model of diabetes in young mice. In that setting, diabetes itself was associated with cardiac stem-cell senescence, pathological myocardial remodeling and cardiac dysfunction, independently of induced ischemia and advanced age. Treating the diabetic mice with dasatinib plus quercetin was associated with improved cardiac function and more favorable cellular readouts.

The different measurements matter. Doppler-based assessments provided information about how the heart fills. The supplied comparison included nine animals per group for the relevant Doppler measurements. Separate experiments examined signals associated with the SASP and the myogenic differentiation of isolated CSCs, with three biological replicates for those specified cellular assays. A cardiomyocyte labeling readout used six biological replicates.

These are complementary results, not interchangeable ones. A filling measurement describes how the organ is functioning. A cell-expression assay describes molecular activity, while a differentiation assay describes what isolated cells can do in culture. The authors interpret the combination as evidence that removing senescent cells rescued cardiac repair and regeneration in diabetic mice. The supplied evidence does not establish that CSC rescue alone explains the cardiac benefit or provide an independently verified lineage account showing that newly functional heart muscle came from the treated CSC population.

Human evidence and mouse evidence answer different questions

The human findings are valuable because they connect diabetes with a senescent, dysfunctional cardiac cell population in actual surgical tissue. They are also limited by the difficulty of obtaining and studying human heart samples. The authors describe those findings as mainly descriptive and hypothesis generating, rather than sufficient to establish direct cause and effect.

The age boundary adds another qualification. The study used an age cutoff below 65 to help separate diabetes from older age, but the authors acknowledge that this threshold is somewhat arbitrary. A comparison restricted to patients in this age range does not show that diabetes-associated senescence behaves identically in older adults, younger adults or people without ischemic heart disease.

The cultured-cell intervention and the mouse experiment address different parts of the argument. Human cultures suggest that clearing senescent cells can improve the expansion and muscle-directed differentiation of the remaining CSC population. Young diabetic mice provide an intervention setting in which cellular changes occurred alongside organ-level functional measurements. Neither setting is a treated-patient trial, and the supplied evidence does not establish how effective dasatinib or quercetin would be individually.

What clearing senescent cells could mean for diabetic hearts

The study points toward a possible way to protect heart repair in type 2 diabetes: preserve a functioning population of cardiac stem and progenitor cells by targeting cells that have become persistently damaged and secretory. If that biology translates beyond cultures and mice, such an approach could eventually help people with type 2 diabetes preserve heart-muscle function rather than allowing diabetes-related stress to erode the repair capacity of the heart.

That possibility remains conditional. Researchers would need to establish that senescent-cell targeting produces safe, sustained functional benefit in patients and that the repair biology observed in these experiments applies to human hearts more broadly. The May 2022 findings make the intervention testable; they do not yet make it a clinical treatment.

Key Sources

• Primary source: Diabetes-Induced Cellular Senescence and Senescence-Associated Secretory Phenotype Impair Cardiac Regeneration and Function Independently of Age.
  DOI or Journal Page · Peer-Reviewed Paper · 2022-05-01